Real-world use of nintedanib for the treatment of interstitial lung disease with progressive pulmonary fibrosis
Medicina Clínica · 2025
DOI: 10.1016/j.medcli.2025.107169 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Medicina Clínica, 2025. Verfasst von Eva Cabrera César und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Virgen de la Victoria, Málaga, Spain. Electronic address: evacabreracesar@gmail.com. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Indoles, Pulmonary Fibrosis, Protein Kinase Inhibitors. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
BACKGROUND: Patients with non-idiopathic interstitial lung diseases can develop progressive pulmonary fibrosis (PPF-ILD). The study objectives were to define the profile of patients with PPF-ILD treated with nintedanib and to assess the effectiveness and safety of this drug in a real-world setting. METHODS: This was a multicenter, prospective, observational study of adult patients with PPF-ILD that initiated treatment with nintedanib in ten Andalusian hospitals (Spain). Demographic data, smoking habit, underlying disease, and diagnosis criteria were recorded. Pulmonary function test results, the dyspnea scale score, and the number of hospitalizations related to PPF-ILD were evaluated at baseline and after 6 and 12 months. Adverse events were recorded. RESULTS: Between July 2021 and March 2023, a total of 145 patients entered the study and were followed up until March 2024; 55% were men and the mean age was 66.6±11.5 years. PPF-ILD was diagnosed based on clinical, radiological and pulmonary function test findings in 97 patients (66.9%). The mean±SD duration of nintedanib therapy was 13.3±10.1 months. Dyspnea improved, although the difference was not statistically significant. FVC % and DLCO % stabilized. The number of hospitalizations related to PPF-ILD was reduced (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario Virgen de la Victoria, Málaga, Spain. Electronic address: evacabreracesar@gmail.com.
- Hospital Universitario Virgen de la Victoria, Málaga, Spain.
- Hospital Universitario Virgen del Rocío, Sevilla, Spain.
- Hospital Universitario Virgen de las Nieves, Granada, Spain.
- Hospital Universitario Virgen de Valme, Sevilla, Spain.
- Hospital Universitario Torrecárdenas, Almería, Spain.
Förderung
- Boehringer Ingelheim
Zitieren
APA
Cabrera César, E., López Garcia, J., Cano Gamonoso, M. B., López Ramirez, C., Jiménez Rodriguez, B., Romero Ortiz, A. D., Palacios Hidalgo, Z., Fole Vázquez, D., Guerrero Zamora, P., Mena Vázquez, N., Hidalgo Molina, A., De La Cruz Morón, I., Espildora Hernández, F., Cruz Medina, A., Lacarcel Bautista, C., Vegas Viñas, A., & Velasco Garrido, J. L. (2025). Real-world use of nintedanib for the treatment of interstitial lung disease with progressive pulmonary fibrosis. Medicina Clínica. https://doi.org/10.1016/j.medcli.2025.107169
Vancouver
Cabrera César E, López Garcia J, Cano Gamonoso MB, López Ramirez C, Jiménez Rodriguez B, Romero Ortiz AD, et al. Real-world use of nintedanib for the treatment of interstitial lung disease with progressive pulmonary fibrosis. Medicina Clínica. 2025. doi:10.1016/j.medcli.2025.107169
BibTeX
@article{CabreraCsar2025,
author = {Cabrera César, Eva and López Garcia, Javier and Cano Gamonoso, Miguel Benitez and López Ramirez, Cecilia and Jiménez Rodriguez, Beatriz and Romero Ortiz, Ana Dolores and Palacios Hidalgo, Zulema and Fole Vázquez, David and Guerrero Zamora, Patricia and Mena Vázquez, Natalia and Hidalgo Molina, Antonio and De La Cruz Morón, Inés and Espildora Hernández, Francisco and Cruz Medina, Antonio and Lacarcel Bautista, Celia and Vegas Viñas, Adriana and Velasco Garrido, José Luis},
title = {Real-world use of nintedanib for the treatment of interstitial lung disease with progressive pulmonary fibrosis},
journal = {Medicina Clínica},
year = {2025},
doi = {10.1016/j.medcli.2025.107169}
}
EUVIMED